Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product Oct 30, 2020 07:00AM
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Oct 12, 2020 09:00AM
Akcea Therapeutics (AKCA) Announces WAYLIVRA to Be Available on the NHS in England Sep 18, 2020 06:17AM
WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England Sep 18, 2020 03:00AM
Ionis Pharmaceuticals (IONS) to acquire remaining stake in Akcea Therapeutics (AKCA) for $18.15/sh Aug 31, 2020 07:21AM
View Older Stories

Aug 31, 2020 06:55AM Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
Aug 31, 2020 06:01AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Highlight Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx))
Aug 31, 2020 06:00AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Present Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx)
Aug 29, 2020 04:00AM Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
Aug 29, 2020 03:30AM Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020
Aug 24, 2020 07:00AM Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020
Aug 18, 2020 07:07AM Akcea Therapeutics (AKCA), Ionis (IONS) to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
Aug 18, 2020 07:00AM Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
Aug 13, 2020 07:00AM Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
Aug 5, 2020 07:00AM Ionis reports second quarter 2020 financial results and recent business achievements
Aug 4, 2020 04:05PM Akcea Reports Financial Results and Highlights for Second Quarter 2020
Jul 22, 2020 07:13AM Akcea Therapeutics (AKCA) Announces Approval for Reimbursement of TEGSEDI in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Jul 22, 2020 07:00AM Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Jul 21, 2020 07:00AM Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast
Jul 20, 2020 07:00AM Akcea Appoints New Senior Vice President, Global Medical Affairs
Jul 9, 2020 07:05AM Akcea Therapeutics (AKCA) Announces Appointment of New Chief Medical Officer
Jul 9, 2020 07:00AM Akcea Announces Appointment of New Chief Medical Officer
Jun 29, 2020 07:00AM Akcea Appoints Tracy Palmer Berns as Chief Compliance Officer
Jun 17, 2020 07:00AM Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Jun 9, 2020 07:00AM Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
Jun 8, 2020 07:02AM Akcea (AKCA) announces approval for reimbursement of TEGSEDI in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
Jun 8, 2020 07:00AM Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
Jun 1, 2020 07:10AM Akcea (AKCA) announces approval for reimbursement of TEGSEDI in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy
Jun 1, 2020 07:00AM Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy
May 28, 2020 07:11AM Akcea (AKCA), Ionis (IONS) Announce Publication of L-T Clinical Data of TEGSEDI in Patients with Polyneuropathy Driven by hATTR Amyloidosis Demonstrating Sustained Improvements
May 28, 2020 07:00AM Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Eve
May 28, 2020 07:00AM Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Eve
May 18, 2020 07:01AM Akcea Therapeutics (AKCA) Announces Appointment of New CFO
May 18, 2020 07:00AM Akcea Announces Appointment of New Chief Financial Officer
May 14, 2020 04:07PM Akcea Therapeutics (AKCA) Announces Approval for Reimbursement of TEGSEDI in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
May 14, 2020 04:05PM Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
May 7, 2020 07:00AM Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer
May 6, 2020 07:00AM Ionis reports first quarter 2020 financial results and recent business achievements
May 5, 2020 04:05PM Akcea Reports Financial Results and Highlights for First Quarter 2020
Apr 21, 2020 07:00AM Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast
Apr 21, 2020 07:00AM Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast
Mar 24, 2020 07:04AM Akcea Therapeutics (AKCA) Announces Dr. Damien McDevitt as CEO
Mar 24, 2020 07:03AM Akcea Therapeutics (AKCA) Announces Appointment of Dr. Damien McDevitt as CEO
Mar 24, 2020 07:00AM Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO
Mar 24, 2020 07:00AM Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO
Mar 11, 2020 07:00AM Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership team
Mar 11, 2020 07:00AM Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership team
Feb 28, 2020 07:00AM Akcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rare”
Feb 28, 2020 07:00AM Akcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rare”
Feb 26, 2020 07:00AM Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
Feb 26, 2020 07:00AM Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
Feb 26, 2020 07:00AM Ionis provides fourth quarter and full year 2019 financial results
Feb 25, 2020 04:05PM Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019
Feb 25, 2020 04:05PM Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019
Feb 18, 2020 07:00AM Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast
View Older Stories